Diagnostic prediction model development using data from dried blood spot proteomics and a digital mental health assessment to identify major depressive disorder among individuals presenting with low mood

•Diagnostic prediction models of depression were developed.•Models showed good discrimination between depressed patients and low mood controls.•Models could potentially be used as a diagnostic aid for detecting depression.•Proteomic biomarkers suggest immune system dysregulation in depression. With...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain, behavior, and immunity behavior, and immunity, 2020-11, Vol.90, p.184-195
Hauptverfasser: Han, Sung Yeon Sarah, Tomasik, Jakub, Rustogi, Nitin, Lago, Santiago G., Barton-Owen, Giles, Eljasz, Pawel, Cooper, Jason D., Ozcan, Sureyya, Olmert, Tony, Farrag, Lynn P., Friend, Lauren V., Bell, Emily, Cowell, Dan, Thomas, Grégoire, Tuytten, Robin, Bahn, Sabine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Diagnostic prediction models of depression were developed.•Models showed good discrimination between depressed patients and low mood controls.•Models could potentially be used as a diagnostic aid for detecting depression.•Proteomic biomarkers suggest immune system dysregulation in depression. With less than half of patients with major depressive disorder (MDD) correctly diagnosed within the primary care setting, there is a clinical need to develop an objective and readily accessible test to enable earlier and more accurate diagnosis. The aim of this study was to develop diagnostic prediction models to identify MDD patients among individuals presenting with subclinical low mood, based on data from dried blood spot (DBS) proteomics (194 peptides representing 115 proteins) and a novel digital mental health assessment (102 sociodemographic, clinical and personality characteristics). To this end, we investigated 130 low mood controls, 53 currently depressed individuals with an existing MDD diagnosis (established current MDD), 40 currently depressed individuals with a new MDD diagnosis (new current MDD), and 72 currently not depressed individuals with an existing MDD diagnosis (established non-current MDD). A repeated nested cross-validation approach was used to evaluate variation in model selection and ensure model reproducibility. Prediction models that were trained to differentiate between established current MDD patients and low mood controls (AUC = 0.94 ± 0.01) demonstrated a good predictive performance when extrapolated to differentiate between new current MDD patients and low mood controls (AUC = 0.80 ± 0.01), as well as between established non-current MDD patients and low mood controls (AUC = 0.79 ± 0.01). Importantly, we identified DBS proteins A1AG1, A2GL, AL1A1, APOE and CFAH as important predictors of MDD, indicative of immune system dysregulation; as well as poor self-rated mental health, BMI, reduced daily experiences of positive emotions, and tender-mindedness. Despite the need for further validation, our preliminary findings demonstrate the potential of such prediction models to be used as a diagnostic aid for detecting MDD in clinical practice.
ISSN:0889-1591
1090-2139
DOI:10.1016/j.bbi.2020.08.011